Notably, in HER2+ BC patients who received neoadjuvant treatment (ie, adriamycin plus CTX and taxanes plus trastuzumab), those who were nonresponsive had lower bacteria α-diversity and more Bacteroides than patients who achieved a pathological complete response. The gene discussed is ERBB2; the disease is breast cancer.